Smaato Launches New SDKs to Support Rich Media Ads

REDWOOD SHORES, Calif., SINGAPORE and HAMBURG, Germany, July 12, 2011 /PRNewswire/
— Smaato Inc., the leading mobile ad optimizer and mobile advertising company, today
announces the rollout of new SDKs designed to support rich media ads on mobile phones
and tablets. The introduction of Smaato’s new rich media solutions will enable developers to
more effectively monetize their applications and or content with a wider range of ad formats.

Smaato Launches New SDKs to Support Rich Media Ads Read More »

Atlantis Resources Corporation completes final phase of fundraising

Singapore, 11 July 2011- Atlantis Resources Corporation, the international tidal energy
developer, has completed the second and final phase of its latest fundraising with an
investment from Singapore’s leading global fund, EDBI (EDB Investments Pte Ltd).
Together with new and existing shareholders, including US investment bank, Morgan
Stanley, a total of SGD$10 million has been raised to finance further research and
development towards commercial deployment.

Atlantis Resources Corporation completes final phase of fundraising Read More »

SpineVision Raises $5 Million

PARIS–(BUSINESS WIRE)–SpineVision announced today that it has raised $5
million from existing investors, one new investor, and Company management.
The cash infusion will be used primarily to accelerate market penetration of the
Company’s next-generation devices for spinal treatment: (1) the minimally
invasive system LUMIS™ and (2) the motion-preservation hybrid-rod system
Flex+™.

SpineVision Raises $5 Million Read More »

CAMBRIDGE, Mass.—June 27, 2011 — FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.

CAMBRIDGE, Mass.—June 27, 2011 — FORMA Therapeutics announced today that it entered into an
agreement granting Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),
exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed
cancer target.

CAMBRIDGE, Mass.—June 27, 2011 — FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target. Read More »

Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore

SINGAPORE–(BUSINESS WIRE)– Inviragen announced today the initiation of
the first clinical trial of the Company’s proprietary Hand, Foot and Mouth
Disease (HFMD) investigational vaccine, INV21, a highly purified virus particle
preparation designed to protect against HFMD caused by enterovirus 71 (EV71)

Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore Read More »